Drug Name:
MONISTAT 1 COMBINATION PACK OTC

Generic Name and Formulations:
Miconazole 1200mg (vaginal supp), miconazole nitrate 2% (topical crm).
Company:
Prestige Brands, Inc.
Therapeutic Use:
Indications for MONISTAT 1 COMBINATION PACK:
Vulvovaginal candidiasis.
Adult:
Insert 1 supp vaginally once at bedtime. Crm: apply twice daily as needed for up to 7 days.
Children:
Not recommended.
Warnings/Precautions:
Use of contraceptive diaphragm or condoms within 3 days, or use of tampons, douches, or spermicides within 7 days: not recommended. Confirm diagnosis by KOH smears +/or cultures. If ineffective, reconfirm diagnosis before repeating therapy. Discontinue if irritation occur. 1st trimester of pregnancy. Nursing mothers.
Pharmacological Class:
Azole antifungal.
Interactions:
May potentiate warfarin.
Adverse Reactions:
Vulvovaginal burning, itching or irritation; edema, cramps, nausea, headache, rash, urticaria.
How Supplied:
Combination Pack—1x1200mg supp (w. applicator or prefilled applicator) + 9g topical crm
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |